**β-Cryptoxanthin- and α-carotene-rich foods have greater apparent bioavailability than β-carotene-rich foods in Western diets**

Betty J. Burri1,2*, Jasmine S. T. Chang2 and Terry R. Neidlinger2

1Department of Nutrition and Food Science and Technology, University of California, Davis, CA 95616, USA
2Western Human Nutrition Research Center, USDA, 430 West Health Sciences Drive, Davis, CA 95616, USA

(Received 9 June 2010 – Revised 19 July 2010 – Accepted 26 July 2010 – First published online 1 September 2010)

Abstract

β-Carotene (BC), β-cryptoxanthin (CX) and α-carotene (AC) are common carotenoids that form retinol. The amount of retinol (vitamin A) from carotenoid-rich foods should depend chiefly on the bioavailability (absorption and circulation time in the body) of carotenoids from their major food sources and the selectivity and reactivity of carotene cleavage enzymes towards them. The objective of the present study was to estimate the apparent bioavailability of the major sources of provitamin A (AC, BC and CX) from the diet by comparing the concentrations of these carotenoids in blood to their dietary intakes. Dietary intakes were estimated by FFQ (three of the present study was to estimate the apparent bioavailability of the major sources of provitamin A (AC, BC and CX) from the diet by comparing the concentrations of these carotenoids in blood to their dietary intakes. Dietary intakes were estimated by FFQ (three studies in this laboratory, n 86; apparent bioavailability calculated for six other studies, n 5738) or by food record (two studies in our laboratory, n 59; apparent bioavailability calculated for two other studies, n 54). Carotenoid concentrations were measured by reversed-phase HPLC. Apparent bioavailability was calculated as the ratio of concentration in the blood to carotenoid intake. Then apparent bioavailabilities for AC and CX were compared to BC. Eating comparable amounts of AC-, CX- and BC-rich foods resulted in 53% greater AC (99% CI 535, 915) concentrations in the blood. This suggests that the apparent bioavailability of CX from typical diets is greater than that of BC. Thus, CX-rich foods might be better sources of vitamin A than expected.

Key words: α-Carotene; β-Carotene; β-Cryptoxanthin; Vitamin A

Provitamin A carotenoids are the major source of vitamin A (VA) in the human diet for most people worldwide(1). Three common carotenoids (α-carotene (AC), β-carotene (BC) and β-cryptoxanthin (CX)) are precursors of VA(1–3). Of the three, BC is the most widely distributed in edible plant sources(4) and usually attains the highest concentrations in human blood(5).

BC is converted to VA by simple mechanisms involving either BC 15,15'-mono-oxygenase (CMO1) for central cleavage or BC 9,10'-mono-oxygenase (CMO2) for eccentric cleavage(6,7). Theoretically, one molecule of BC can be cleaved by CMO1 into two molecules of VA. However, BC-rich foods do not contribute as much VA to the body as these reaction mechanisms would lead one to expect. The VA activity of carotenoids is denoted by retinol activity equivalents (RAE). Currently, the international estimate of VA activity is that 12 mg of BC from food are required to produce 1 mg of retinol, for an RAE ratio of 12.1(8,9). The reasons for this relatively poor RAE conversion ratio are multifactorial(10,11). However, a major reason appears to be poor absorption of BC from its most important food sources(10,11). Dietary sources of BC include orange and bright green vegetables such as carrot, sweet potato, pumpkin, broccoli and collard greens, as well as other foods like red palm oil and vitamin supplements(12). The amount of VA formed from BC depends on the source of BC. BC in orange fruits and vegetables appears to be better absorbed and utilised, or more bioavailable, than BC in leafy green vegetables(1). Therefore, orange fruits and vegetables are better sources of VA than leafy green vegetables with comparable BC concentrations.

Current estimates of RAE for AC- and CX-rich foods are half that of BC, so that 24 mg of AC or CX from food are expected to produce 1 mg of retinol, for an RAE ratio of 24:1(12,13). RAE ratios for AC and CX do not appear to be estimated empirically with CX- or AC-rich foods, or to be based on carotenoid cleavage reaction kinetics(2,12–14). Instead, it appears that RAE for AC and CX were set at half the RAE for BC because one molecule of BC can be cleaved to form two molecules of retinal,

**Abbreviations:** AC, α-carotene; BC, β-carotene; bio, bioavailable carotenoid; CMO1, BC 15,15'-mono-oxygenase; CMO2, BC 9,10'-mono-oxygenase; CX, β-cryptoxanthin; RAE, retinol activity equivalents; VA, vitamin A.

*Corresponding author:* B. J. Burri fax +1 530 752 5271, email betty.burri@ars.usda.gov
whereas one molecule of AC or CX on cleavage can only yield one molecule of retinol. However, the RAE of BC-rich foods seem to depend more on how well BC is absorbed from food than on the reaction mechanisms that form VA. Therefore, we hypothesised that the RAE of AC- and CX-rich foods would also depend primarily on how well these carotenoids were absorbed from food and retained in the body. Thus, comparing apparent bioavailability of BC, AC and CX from the diet would be useful for delineating the relative importance of major provitamin A carotenoids. We further hypothesised that a good indicator of how well the carotenoids are absorbed and retained in the body would be their concentrations in the blood.

AC is found in a limited number of orange vegetables such as carrots and pumpkin. Good food sources of AC also tend to be good food sources of BC. CX, on the other hand, is found primarily in orange fruits such as mandarins, oranges, peaches and chillies that are not good sources of BC. Since the most important food sources of CX differ from those of AC and BC, the absorption of CX from the diet may also differ. Herein we describe our investigations comparing dietary intakes of BC, CX and AC to their serum concentrations to determine the relative bioavailability of these carotenoids from the diet. Three studies were conducted in our own laboratory. In addition, we identified and analysed data from other recent (post 2000) human nutrition studies that reported both dietary intakes and concentrations of AC, BC and CX in the blood.

Experimental methods

Chemicals and supplies

Retinyl palmitate, retinol, retinyl acetate, AC and BC standards were purchased from Sigma Aldrich Chemical Company (St Louis, MO, USA). CX standard was purchased from Chromadex (Irvine, CA, USA). Purities of BC and CX standards were checked by HPLC with diode array detection and were found to be 95 and 94%, respectively. All other chemicals and solvents were obtained from Sigma, Fisher Scientific (Pittsburgh, PA, USA) or J.T. Baker (Phillipsburg, NJ, USA). All the chemicals were reagent or HPLC grade.

Human studies

We conducted three human nutrition studies that derived dietary intake estimates and serum concentrations of AC, BC and CX between 1996 and 2006. All the studies were conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Institutional Review Board of the University of California Davis. Written consent was obtained from all the subjects. The main purpose of these studies was to test methods for improving dietary analysis or to investigate antioxidant status in people with disabilities. The study plans and demographic characteristics of the volunteers for these studies were published elsewhere. All the participants were healthy adult volunteers, whose age ranged from 18 to 69 years. Subjects in these studies could consume a daily multivitamin supplement containing up to 2000 IU (1.2 mg) BC, but could not consume carotenoid supplements in higher dosages or megavitamins. In the case of Dixon et al., dietary information was re-analysed in 2001, after more carotenoid information was added to the United States Department of Agriculture database. The carotenoid data herein are presented for the first time.

Dietary intake estimates

Dietary intakes were estimated for 6 months before the study by the Block FFQ (Block Dietary Systems, Berkeley, CA, USA; HHHQ, Scantron version 98.2, Scantron Corporation, Santa Ana, CA, USA). Food frequency estimates were collected on the same day as the blood draw. Food records (3 d) were collected on two non-consecutive week and one weekend day, and were analysed with Nutrition Data System for Research (NDS-R) software 4.02 (http://www.ncc.umn.edu/products/ndsr.html). These dietary intake estimates cover different amounts of time. Food records from all but three subjects were collected within 3 weeks after the blood draw and covered a 1-week reporting period. The FFQ covers 6 months of usual intake before the blood draw. Thus, the 3 d record reflects short-term intake, while the food frequency reflects long-term intake.

HPLC

Carotenoids from human plasma or serum were extracted as described previously. Following an overnight fast, 15–70 ml of blood (depending on the study) were collected from an antecubital vein. Plasma was harvested within 3 h of collection and stored at –80°C until use. Plasma samples (500 µl) were mixed with 1 ml of 95% aqueous ethanol containing 5 mg/l butylated hydroxytoluene, vortexed for 60 s and then mixed with an equal volume of hexane. The hexane layer was removed, and the extraction was repeated. The combined hexane layers were dried under a stream of nitrogen. Finally, the sample was re-suspended in 100 µl solvent buffer.

HPLC analysis was performed with an Agilent 1100 gradient chromatograph (Waldbronn, Germany). Data analyses were carried out using a HP Chemstation for LC 3D revision A.08.03 (847) for Agilent Technologies (Hewlett-Packard, Waldbronn, Germany).

Human plasma samples were run by a reversed-phase binary gradient method. Solvent A contained acetonitrile–tetrahydrofuran–methanol–ammonium sulphate
(85:5:5:5, by vol.), and solvent B contained acetonitrile—tetrahydrofuran—methanol—ammonium sulphate (55:35:5:5, by vol.). HPLC was run at 1·0 ml/min on a Prodigy 5 micron C18 250 × 4·6 mm column (Phenomenex, Torrance, CA, USA). Total run time was 48 min. The run was 0–10·0 min, 5 % solvent B; 10·0–29·0 min increasing linearly to 95 % solvent B; 29·0–35·9 min, maintaining 95 % solvent B; 35·9–36·0 min, abruptly decreasing to 60 % solvent B; maintaining 60 % solvent B from 36·0 to 44·9 min; then abruptly decreasing to 5 % solvent B at 45 min. The column re-equilibrated with 5 % solvent B from 45·0 to 48·0 min. Retinyl acetate (measured at 325 nm) was used as the internal standard. This method separates \(\alpha\)-cryptoxanthin and CX, and all \(\text{trans-BC}\) and \(\text{cis-BC}\). The BC and CX data reported are, respectively, for BC and CX alone, not in combination with their isomers (\(\alpha\)-cryptoxanthin and \(\text{cis-BC}\), respectively).

**Literature review and analysis of studies**

We searched reference databases Medline, Food Science and Technology Abstracts and Agricola between October 2008 and April 2010 to identify studies that reported dietary intakes and concentrations of AC, BC and CX in the blood. Literature searches were limited to human observational studies published subsequent to 2000, after more carotenoid concentrations had been added to the United States Department of Agriculture Nutrient Database for Standard Reference. Key words used for carotenoids were ‘caroten*’, ‘cryptoxanthin’, ‘RN 7235-40-7’, ‘RN 7488-99-5’ and ‘RN 472-70-8’. Key words for dietary intake were ‘dietary intake’, ‘diet’, ‘food frequency’ or ‘food record’. Key words for blood were ‘blood’, ‘serum’ or ‘plasma’. Keywords for human were ‘human*’ or ‘subject*’. The articles retrieved were hand searched to retrieve other relevant articles. A study was included if it met all of the following criteria: it was a human study published in English as a full-length study in a peer-reviewed journal; it reported mean or median carotenoid concentrations in the blood and total dietary intake estimates (as opposed to the intake of major foods or food groups) for AC, BC and CX. We found twelve studies that met these criteria.

**Table 1. Mean dietary intakes estimated from food records v. mean concentrations of \(\alpha\)-carotene (AC), \(\beta\)-carotene (BC) and \(\beta\)-cryptoxanthin (CX) in the blood**

<table>
<thead>
<tr>
<th>Study population</th>
<th>(n)</th>
<th>AC ((\mu)mol/d)</th>
<th>BC ((\mu)mol/d)</th>
<th>CX ((\mu)mol/d)</th>
<th>AC ((\mu)mol/l)</th>
<th>BC ((\mu)mol/l)</th>
<th>CX ((\mu)mol/l)</th>
<th>ACbio/BCbio</th>
<th>CXbio/BCbio</th>
<th>Date of publication (references)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td>49</td>
<td>0·96</td>
<td>7·14</td>
<td>0·21</td>
<td>0·13</td>
<td>0·58</td>
<td>0·26</td>
<td>1·68</td>
<td>15·1</td>
<td>2010(15)</td>
</tr>
<tr>
<td>Adult</td>
<td>10</td>
<td>0·88</td>
<td>5·10</td>
<td>0·72</td>
<td>0·12</td>
<td>0·41</td>
<td>0·28</td>
<td>1·67</td>
<td>4·32</td>
<td>1996(16)*</td>
</tr>
<tr>
<td>Adult</td>
<td>30</td>
<td>2·98</td>
<td>7·57</td>
<td>0·38</td>
<td>0·11</td>
<td>0·62</td>
<td>0·25</td>
<td>0·45</td>
<td>8·00</td>
<td>2005(20)</td>
</tr>
<tr>
<td>Female</td>
<td>24</td>
<td>1·30</td>
<td>3·89</td>
<td>0·16</td>
<td>0·27</td>
<td>1·01</td>
<td>0·43</td>
<td>0·75</td>
<td>9·57</td>
<td>2008(11)</td>
</tr>
<tr>
<td>Mean</td>
<td>1·53*</td>
<td>5·92*</td>
<td>0·37*</td>
<td>0·16*</td>
<td>0·68*</td>
<td>0·30*</td>
<td>1·14</td>
<td>9·25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEM (df = 4)</td>
<td>0·49</td>
<td>0·87</td>
<td>0·13</td>
<td>0·04</td>
<td>0·15</td>
<td>0·04</td>
<td>0·00</td>
<td>0·32</td>
<td>2·24</td>
<td></td>
</tr>
</tbody>
</table>

\(\alpha\)-\(\beta\): Superscript letters indicate significant differences between mean dietary intakes or between mean carotenoid concentrations in the blood (*P* < 0·05).

* Dietary intake re-analysed 2001.

**Mathematical analysis**

All dietary intake estimates were converted into \(\mu\)mol carotenoid/d. All the blood (serum or plasma) concentrations were converted into \(\mu\)mol/l. Then, carotenoid concentrations in the blood were divided by dietary intakes of that carotenoid to estimate the amount of carotenoid absorbed and circulated (bioavailable carotenoid (bio)) in the blood (e.g. \(\text{AC}_{\text{bio}}/\text{AC}_{\text{diet}} = \text{AC}_{\text{bio}}\)). Since BC is the major carotenoid source of VA, we used it as our standard of comparison. Comparisons of bioavailability are given as the ratios of \(\text{AC}_{\text{bio}}/\text{BC}_{\text{bio}}\) and \(\text{CX}_{\text{bio}}/\text{BC}_{\text{bio}}\). Mean ratios of \(\text{AC}_{\text{bio}}/\text{BC}_{\text{bio}}\) and \(\text{CX}_{\text{bio}}/\text{BC}_{\text{bio}}\) were calculated by averaging the \(\text{AC}_{\text{bio}}/\text{BC}_{\text{bio}}\) and \(\text{CX}_{\text{bio}}/\text{BC}_{\text{bio}}\) ratios derived for each subpopulation.

Descriptive statistics are presented as means with their standard errors and 99 % CI. Results from the studies were reviewed for their suitability for meta-analysis(20). However, all of these studies are observational, most are small, and the subject selection criteria and analysis methods diverse. Furthermore, none of the studies in this report was a planned comparison of the bioavailability of AC, BC and CX from the diet. We concluded that formal meta-analysis of the data was premature. We were able to examine the relationships between carotenoid concentrations in the blood and diet using the Student’s \(t\) test, ANOVA and linear regression. All the statistical comparisons were two-sided. Statistics were calculated with SigmaPlot (Systat Software, Inc., San Jose, CA, USA).

**Results**

**Dietary intakes**

Dietary intakes of carotenoids estimated by food record (mean or median when noted) are reported in Table 1. Results for dietary intake estimates calculated from FFQ are shown in Table 2 (for our laboratory data) and Table 3 (for literature data). Data are listed by the subpopulations studied in the original reports (for example, men and women; normal weight, overweight and obese).

One subpopulation found in our literature search (females with osteoporosis(21)) was an outlier, as determined by its \(z\) score. This population had very high dietary intakes.
Table 2. Mean dietary intakes estimated from FFQ v. mean concentrations of α-carotene (AC), β-carotene (BC) and β-cryptoxanthin (CX) in the blood

<table>
<thead>
<tr>
<th>Study population</th>
<th>Mean dietary intake (μmol/d)</th>
<th>Mean concentration in blood (μmol/l)</th>
<th>Ratio of apparent bioavailability</th>
<th>Date of publication (references)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
<td>BC</td>
<td>CX</td>
<td>ACbio/BCbio</td>
</tr>
<tr>
<td>Adult (control)</td>
<td>35</td>
<td>1·38 6·37 0·24</td>
<td>0·11 0·62 0·28</td>
<td>0·82 12·0</td>
</tr>
<tr>
<td>Adult (physically disabled)</td>
<td>22</td>
<td>1·17 5·26 0·20</td>
<td>0·09 0·38 0·18</td>
<td>1·07 12·4</td>
</tr>
<tr>
<td>Adult</td>
<td>49</td>
<td>1·34 6·29 0·26</td>
<td>0·13 0·58 0·26</td>
<td>1·05 11·3</td>
</tr>
<tr>
<td>Adult</td>
<td>10</td>
<td>0·72 4·93 0·24</td>
<td>0·12 0·41 0·28</td>
<td>2·00 14·1</td>
</tr>
<tr>
<td>Mean</td>
<td>1·15a 5·72b 0·23c</td>
<td>0·11a 0·50b 0·25c</td>
<td>1·23 12·4</td>
<td></td>
</tr>
<tr>
<td>SEM (df = 3)</td>
<td>0·15 0·36 0·01</td>
<td>0·01 0·06 0·02</td>
<td>0·26 0·60</td>
<td></td>
</tr>
</tbody>
</table>

bio, Bioavailable.

* Superscript letters indicate significant differences between mean dietary intakes or between mean carotenoid concentrations in the blood (P<0·05).
*† Dietary information re-analysed 2001.

intakes of VA and BC, and considerably had higher ACbio and BCbio values than any other subpopulation. Osteoporosis is linked to high VA intakes(22), and these high intakes or the medications that this population takes appear to have influenced their carotenoid absorption or metabolism. If this subpopulation was included in our calculations, none of the present results would differ significantly from those we report.

Mean dietary carotenoid intakes estimated by 3 d food records ranged from 0·88 to 2·98, 3·89 to 7·57 and 0·16 to 0·72 μmol/d for AC, BC and CX, respectively (Table 1). These were generally somewhat lower than mean dietary intakes estimated by food frequency, which ranged from 0·27 to 2·31, 3·12 to 9·80 and 0·18 to 0·89 μmol/d for AC, BC and CX, respectively (Tables 2 and 3). A comparison of mean dietary intakes (Tables 1–3) for the subpopulations shows that intakes of BC were always greater than the intakes of AC (P<0·0001), which in turn were usually greater than the intakes of CX (P<0·0001).

Mean dietary intakes of AC and BC in these subpopulations were positively correlated with each other (r2 0·48, P<0·0001). Mean dietary intakes of CX were not correlated with either AC or BC (r2 0·01 and 0·12, respectively). Because of the small number of reports for each subpopulation, no conclusions could be drawn on differences in subpopulations, though men usually had higher mean carotenoid intakes than women did (P<0·01).

Table 3. Mean dietary intakes estimated from FFQ v. mean concentrations of α-carotene (AC), β-carotene (BC) and β-cryptoxanthin (CX) in the blood (from literature)

<table>
<thead>
<tr>
<th>Study population</th>
<th>Mean dietary intake (μmol/d)</th>
<th>Mean carotenoid concentration in blood (μmol/l)</th>
<th>Ratio of apparent bioavailability</th>
<th>Date of publication (references)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
<td>BC</td>
<td>CX</td>
<td>ACbio/BCbio</td>
</tr>
<tr>
<td></td>
<td>0·27 5·67 0·18</td>
<td>0·07 0·62 0·17</td>
<td>2·39 8·8</td>
<td>2007(56)</td>
</tr>
<tr>
<td></td>
<td>0·47 5·04 0·23</td>
<td>0·07 0·72 0·18</td>
<td>1·05 5·5</td>
<td>2007(56)</td>
</tr>
<tr>
<td></td>
<td>1·28 6·42 0·27</td>
<td>0·10 0·23 0·09</td>
<td>2·24 9·2</td>
<td>2005(57)</td>
</tr>
<tr>
<td></td>
<td>1·82 8·66 0·30</td>
<td>0·07 0·26 0·09</td>
<td>1·31 10·4</td>
<td>2005(57)</td>
</tr>
<tr>
<td></td>
<td>1·46 7·00 0·31</td>
<td>0·13 0·30 0·11</td>
<td>2·05 8·6</td>
<td>2005(57)</td>
</tr>
<tr>
<td></td>
<td>1·69 7·81 0·23</td>
<td>0·08 0·29 0·11</td>
<td>1·24 12·5</td>
<td>2005(57)</td>
</tr>
<tr>
<td></td>
<td>1·34 7·45 0·50</td>
<td>0·06 0·20 0·11</td>
<td>1·73 8·1</td>
<td>2007(58)</td>
</tr>
<tr>
<td></td>
<td>1·55 8·11 0·57</td>
<td>0·10 0·30 0·14</td>
<td>1·65 6·4</td>
<td>2007(58)</td>
</tr>
<tr>
<td></td>
<td>1·43 7·32 0·49</td>
<td>0·14 0·39 0·13</td>
<td>1·83 5·0</td>
<td>2007(58)</td>
</tr>
<tr>
<td></td>
<td>1·48 8·00 0·56</td>
<td>0·08 0·25 0·14</td>
<td>1·67 7·7</td>
<td>2007(58)</td>
</tr>
<tr>
<td></td>
<td>3·12 0·33</td>
<td>0·06 0·20 0·10</td>
<td>1·09 4·8</td>
<td>2007(58)</td>
</tr>
<tr>
<td></td>
<td>0·68 5·51 0·24</td>
<td>0·09 0·57 0·42</td>
<td>1·27 16·0</td>
<td>2009(23)</td>
</tr>
<tr>
<td></td>
<td>0·96 5·92 0·44</td>
<td>0·12 0·43 0·17</td>
<td>1·64 5·3</td>
<td>2009(59)</td>
</tr>
<tr>
<td></td>
<td>0·93 6·04 0·50</td>
<td>0·11 0·37 0·22</td>
<td>1·97 7·2</td>
<td>2009(59)</td>
</tr>
<tr>
<td></td>
<td>0·68 5·73 0·45</td>
<td>0·09 0·31 0·15</td>
<td>2·40 6·1</td>
<td>2009(59)</td>
</tr>
<tr>
<td></td>
<td>0·66 5·08 0·47</td>
<td>0·11 0·33 0·18</td>
<td>2·61 5·8</td>
<td>2009(59)</td>
</tr>
<tr>
<td></td>
<td>2·31 9·58 0·58</td>
<td>0·08 0·48 0·16</td>
<td>0·70 5·6</td>
<td>2009(60)</td>
</tr>
<tr>
<td></td>
<td>2·10 9·80 0·62</td>
<td>0·11 0·71 0·27</td>
<td>0·72 6·1</td>
<td>2009(60)</td>
</tr>
<tr>
<td></td>
<td>0·86 6·63 0·85</td>
<td>0·12 0·47 0·15</td>
<td>1·95 2·5</td>
<td>2002(61)</td>
</tr>
<tr>
<td></td>
<td>0·83 7·01 0·89</td>
<td>0·14 0·60 0·19</td>
<td>1·96 2·5</td>
<td>2002(61)</td>
</tr>
<tr>
<td>Mean</td>
<td>1·18a 6·79b 0·45c</td>
<td>0·10a 0·40b 0·16c</td>
<td>1·67 7·2</td>
<td></td>
</tr>
<tr>
<td>SEM (df = 19)</td>
<td>0·12 0·36 0·04</td>
<td>0·006 0·04 0·02</td>
<td>0·12 0·72</td>
<td></td>
</tr>
</tbody>
</table>

bio, Bioavailable.

* Superscript letters indicate significant differences between mean dietary intakes or between mean carotenoid concentrations in the blood, P<0·05.
*† Medians, converted from mg/d.
in the blood ranged from 0·06 to 0·27, 0·20 to 1·10 and 0·09 to 0·43 μmol/l, respectively. Mean concentrations of BC were always greater than mean concentrations of CX \((P<0·00001)\) or AC \((P<0·00001)\) measured in the same study population. Mean concentrations of CX were greater than concentrations of AC in all but three of twenty-eight subpopulations \((P<0·00001)\). Mean carotenoid concentrations in the blood in these studies (Tables 1–3) were well within the reported US ranges of 0·02–0·47, 0·04–2·26 and 0·03–0·70 μmol/l for AC, BC and CX, respectively\(^{1,5}\).

Mean carotenoid concentrations in the blood were correlated with each other, so that a subpopulation that had high concentrations of BC also tended to have high concentrations of AC and CX. The correlations between AC and BC, AC and CX, and BC and CX were \(r^2 0·41\), \(P<0·0002\); \(r^2 0·39\), \(P=0·0012\) and \(r^2 0·57\), \(P=0·00001\), respectively.

### Comparing carotenoid bioavailability

Tables 1–3 compare the impact of dietary intakes on concentrations of carotenoids in the blood. The ratios of AC\(_{\text{bio}}\)/BC\(_{\text{bio}}\) vary from study to study. However, ratios are quite consistent, being >1 in all but five of the twenty-eight comparisons (Fig. 1). The mean ratio of AC\(_{\text{bio}}\)/BC\(_{\text{bio}}\) was 1·53 (99 % CI 1·23, 1·83). Thus, eating comparable amounts of AC- and BC-rich foods resulted in 53 % higher AC concentrations in the blood.

Even more remarkably, the ratios of CX\(_{\text{bio}}\)/BC\(_{\text{bio}}\) were always >1, and in all but four of the twenty-eight comparisons, the ratio of CX\(_{\text{bio}}\)/BC\(_{\text{bio}}\) was >5 (Fig. 1). The mean ratio of CX\(_{\text{bio}}\)/BC\(_{\text{bio}}\) was 8·25 (99 % CI 6·35, 10·15). Thus, eating comparable amounts of CX- and BC-rich foods resulted in 725 % greater CX concentrations in the blood. In a single study of adipose tissue\(^ {23} \), the ratio of AC\(_{\text{bio}}\)/BC\(_{\text{bio}}\) was 1·32, and the ratio of CX\(_{\text{bio}}\)/BC\(_{\text{bio}}\) was 7·0, similar to the mean ratios obtained for blood.

We observed few consistent differences in the ratios of AC\(_{\text{bio}}\)/BC\(_{\text{bio}}\) or CX\(_{\text{bio}}\)/BC\(_{\text{bio}}\) between population subgroups, probably because of the small number of studies available for our analysis, and the variability created by differences in the test methods and populations of these studies.

### Discussion

Mean dietary intakes and concentrations of AC, CX and BC in the blood varied widely from study to study. Despite this variability, several relationships between carotenoid concentrations in the subpopulations could be observed. Mean dietary intakes and concentrations of BC in the blood were always greater than those of AC or CX in the studies reported herein, which appears to be typical worldwide\(^ {1,5,5,8} \). Mean dietary intakes of AC and BC in the subpopulations that we studied were positively correlated with each other, which was not surprising since these carotenoids are often found in the same foods\(^ {43} \).
of AC from the diet. First, AC concentrations in diets may be poorly reported and thus underestimated. The difficulties in estimating dietary intakes are well known [26,27]. AC concentrations might be more under-reported than BC concentrations because AC is found in smaller concentrations, in fewer foods. Secondly, the food composition data for AC- and BC-rich food may not reflect their current nutrient content well. The number of foods and plant varieties is immense and evolves with time. Furthermore, carotenoid concentrations in plants vary with growing conditions, handling, storage, cooking practices and plant variety, making nutrient intakes from dietary intakes difficult to estimate [4,15,20]. If the carotenoid concentrations of an AC-rich food such as carrots increased with time because of the improvements in plant varieties, it is possible that the real AC concentrations in foods are higher than the concentrations reported by the United States Department of Agriculture database.

However, the difference in apparent bioavailability between AC- and BC-rich foods in the diet could be caused by physiological mechanisms. First, dietary intakes of AC are usually much lower than intakes of BC [1,3,5] (Tables 1–3). There is some evidence that lower concentrations of carotenoids are absorbed better than higher concentrations of carotenoids from food. If this was so, it could account for the difference in apparent bioavailability between AC- and BC-rich foods [29,30]. However, most reports have found little or no effect of carotenoid concentration on absorption [31–35]. Overall, there is little evidence of a strong concentration effect on AC or BC absorption, except during high pharmacological intakes.

Secondly, AC might circulate longer in the blood than BC. This is likely because BC is preferentially cleaved to form VA by both carotenoid cleavage enzymes CMO1 and CMO2 [6,7]. Data from carotenoid depletion studies support the possibility that AC circulates in the blood longer than BC. These results suggest that concentrations of all carotenoids decreased in a similar way by first-order kinetic processes. Differences in carotenoid circulation time \( t_{1/2} \) were not large [36]; however, the \( t_{1/2} \) of carotenoid disappearance from the blood was 45 d for AC, 37 for BC and 39 for CX. This difference in half-life probably accounts for the differences in apparent bioavailability that we observed between AC and BC.

However, AC may really be absorbed better than BC from mixed diets. Although BC is available in dietary supplements that are absorbed well [1,37], it is also found in a variety of foods including green leafy vegetables, which have poor bioavailability [1,10,26,38]. Thus, the overall absorption of AC from the diet might be greater than that of BC. Further research on the current concentration of carotenoids in foods, their absorption and circulation in the body and their interactions with CMO1 and CMO2 is necessary to determine whether the bioavailability of AC is better than that of BC from mixed diets.

The 7-fold difference between the apparent bioavailability of CX and BC in mixed diets is more difficult to explain as a product of methodological issues, even though artefacts associated with dietary assessment, and nutrient composition of foods could occur [31–35]. As with AC and BC absorption, there is little evidence of a strong concentration effect on CX absorption [31–35]. Finally, it is also unlikely that the small differences in circulation time [36] between CX and BC (37 and 39 d, respectively) could account for this large difference in apparent bioavailability.

Another explanation for the apparently high bioavailability of CX from the diet is that CX might be formed from BC. However, the metabolism of BC has been studied by radioisotope [49,50] and cell culture methods [41], and these reports do not suggest that CX is a major metabolite of BC. Furthermore, the correlation between dietary intake estimates and serum concentrations of CX is no worse than that of other carotenoids [1,11], as it might be if significant amounts of CX in the blood were actually being formed from BC. Thus, it appears that CX absorption from its major dietary sources must be high, compared with AC and BC.

Few studies have compared CX, BC and especially AC absorption from foods under controlled conditions. Studies in human subjects suggest that CX is very well absorbed [42], while studies in the preruminant calf model suggest that AC is absorbed similarly to BC [43]. Cell culture studies simulating carotenoid digestion are contradictory, suggesting that CX can be digested with similar [44], greater [35] or lesser [46] efficiency than BC, probably depending on the specific food chosen and on reaction conditions.

Other studies have investigated how bioefficacious CX or AC are in maintaining VA status, which probably depends mainly on how well the carotenoid is absorbed and retained, as well as on how well it functions as a substrate for the carotenoid cleavage enzymes CMO1 and CMO2. BC is clearly the preferred substrate for CMO1 and CMO2, but these enzymes also have significant activities with AC and CX [47,48]. There are few studies on the bioefficacy of AC, and most of the studies on the bioefficacy of CX were conducted with purified chemicals and used in inappropriate animal models such as rats, mice or chickens [2,49,50]. These studies estimated that CX was 56 and 22% as bioactive as BC in the rat [4,49], and 55 or 98% as active in the chick [50,51]. However, their results appear similar to the two reports that have compared the efficacy of VA formation by BC and CX in an accepted animal model of human carotenoid metabolism, the Mongolian gerbil, which estimated efficacies of over 90% [14,52]. A single study investigated the bioefficacy of AC in the Mongolian gerbil and found it to be half as effective as BC [53].

A caveat about our research is that BC\textsuperscript{bio} is probably increased by vitamin supplement intake, since many vitamin supplements contain BC in a highly bioavailable form. It is not possible for us to estimate the influence of vitamin supplement intakes on BC\textsuperscript{bio} because many of the studies that we surveyed do not estimate vitamin...
supplement intake. Furthermore, the intake of vitamin supplements is restricted in many nutrition studies. For example, the subjects in our studies could consume no more than 1·2 mg BC/d as vitamin supplements, and only 22% of our study population consumed any vitamin supplements.

Further studies are needed on the absorption of AC and CX from foods, and on their metabolism in the body. However, it appears that CX might have 7-fold greater bioavailability from its primary food sources than do AC or BC. Although the efficacy of CX in forming VA in humans is not established, animal model studies suggest that it is between 22 and 98% as active as BC. These results, taken together, suggest that CX-rich foods may be a better source of VA than currently assumed. This is especially interesting, because the citrus fruits that are rich in CX are often consumed as whole fruit, instead of in mixed dishes with fat. The absorption of most carotenoids, including BC, is greatly improved by incorporating fat in the diet(52,54). Most VA deficiency occurs in populations who also have little fat in their diet(1,3), so if CX is absorbed well without fat, then CX-rich foods might be especially useful for dietary interventions to prevent VA deficiency.

Acknowledgements

This work was supported by the United States Department of Agriculture and the Paralyzed Veterans of America (Spinal Cord Research Grant 1803). There are no conflicts of interest. B. J. B. designed the research, analysed the data, wrote the paper and had primary responsibility for the final content. T. R. N. and J. S. T. C. conducted the research. All the authors read and approved the final manuscript.

References


